FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
|Articles|June 15, 2018
- BioPharm International-06-15-2018
- Volume 2018 eBook
- Issue 2
Comparing the Supply Lifecycle of Bioreactors
Author(s)Kenneth Clapp
Understanding differences in bioreactor lifecycle, design space, and product platforms is important for selecting a bioreactor type.
Advertisement
The experience gained and knowledge compiled from legacy biomanufacturing operations establish a reference. This reference can benefit a thorough assessment of new methods and technologies, and it can aid in the transition or adoption of new approaches. With respect to stainless-steel and single-use bioreactors, lifecycle, design space, and product platform concepts are discussed in this article.
Read
Article Details
BioPharm International
eBook: Single-Use Systems 2018
Vol. 31
June 2018
Pages: 41–46
Citation
When referring to this article, please cite it as K. Clapp, "Comparing the Supply Lifecycle of Bioreactors," Single-Use Systems eBook (June 2018).
Articles in this issue
over 8 years ago
Considering Silicone Tubing and Assembliesover 8 years ago
Qualification of Single-Use Systemsover 8 years ago
Managing Quality in Single-Use Systemsover 8 years ago
Assurance of Supplyover 8 years ago
Biosimilars and Biobetters Strategies and Challengesover 8 years ago
An Integrated Approach to Shipping Liquid in Single-Use Systemsover 8 years ago
Single-Use Boosts Fill/Finish in Commercial BiomanufacturingAdvertisement
Related to this article
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
Bristol Myers Squibb's GPRC5D-Directed CAR T Cell Therapy Meets Primary Endpoint in Multiple Myeloma
Bristol Myers Squibb reported positive topline phase 2 results for arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy, in patients with quadruple-class exposed relapsed and refractory multiple myeloma who had already received a prior BCMA-targeted therapy.
Cipla's US subsidiary secured exclusive rights to commercialize QL2107, Qilu Pharmaceutical's phase 3 biosimilar candidate to Keytruda, ahead of the reference biologic's anticipated 2028 patent expiration.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement